H. Becker

发表

Publication List 2010, Part 1

E. Adam, C. McGrath, C. Zimmermann, 2022 .

Microbial metabolism of IBD-drugs - current evidence and clinical implementations.

D. Jonkers, J. Penders, H. Becker, 2021, Gastroenterology.

Higher in vitro mucin degradation, but no increased paracellular permeability by faecal water from Crohn’s disease patients

D. Jonkers, J. Penders, F. Stassen, 2022, bioRxiv.

Higher Prevalence of Bacteroides fragilis in Crohn’s Disease Exacerbations and Strain-Dependent Increase of Epithelial Resistance

P. Savelkoul, C. Jamin, D. Jonkers, 2020, bioRxiv.

Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease

D. Jonkers, J. Penders, H. Becker, 2023, Frontiers in Microbiology.

Anemia and Elevated Systemic Levels of Vascular Endothelial Growth Factor (VEGF)

C. Lautenschläger, J. Dunst, A. Becker, 2002, Strahlentherapie und Onkologie.

Metagenomic Profiling of Fecal-Derived Bacterial Membrane Vesicles in Crohn’s Disease Patients

D. Jonkers, J. Penders, P. Savelkoul, 2021, Cells.

How to Count Our Microbes? The Effect of Different Quantitative Microbiome Profiling Approaches

P. Savelkoul, M. Hornef, L. Bervoets, 2020, Frontiers in Cellular and Infection Microbiology.

Intestinal organoid culture model is a valuable system to study epithelial barrier function in IBD

A. Masclee, D. Jonkers, P. Xu, 2017, Gut.

Interleukin-28A Induces Epithelial Barrier Dysfunction in CD Patient-derived Intestinal Organoids.

A. Masclee, D. Jonkers, M. Pierik, 2021, American journal of physiology. Gastrointestinal and liver physiology.

Common drugs alter microbial protein expression, but not composition in fecal cultures from Crohn’s disease patients

D. Jonkers, J. Penders, H. Becker, 2023, bioRxiv.